**Clinical Study Protocol (CSP) Template**

**1. Protocol Overview**

Protocol Title: #Protocol Title#

Protocol Number: #Protocol Number#

Study Phase: #Study Phase#

Sponsor Name and Regulatory Details: #Sponsor Name and Regulatory Details#

**2. Objectives and Endpoints**

Primary Objective: #Primary Objective#

Secondary Objectives: #Secondary Objectives#

**Endpoints**:

Primary Endpoint

#HC\_AI\_ Primary\_Endpoint#

Secondary Endpoint

#HC\_AI\_Secondary\_Endpoint#

**3. Schedule of Assessments**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Procedure / Assessment | Screening | Day 1 | Week 2 | Week 4 | Week 8 | End of Study | Notes / Conditions |
| Informed Consent |  |  |  |  |  |  |  |
| Inclusion/Exclusion Criteria |  |  |  |  |  |  |  |
| Physical Examination |  |  |  |  |  |  |  |
| Vital Signs |  |  |  |  |  |  |  |
| ECG |  |  |  |  |  |  |  |
| Lab Tests – Hematology/Chemistry |  |  |  |  |  |  |  |
| Study Drug Administration |  |  |  |  |  |  |  |
| Adverse Events |  |  |  |  |  |  |  |
| Efficacy Assessment – Tumor Scan |  |  |  |  |  |  |  |
| PK Sampling |  |  |  |  |  |  |  |

**4. Study Design**

Overall Design:

#HC\_AI\_Overall\_Design#

Inclusion/Exclusion Criteria:

#HC\_AI\_Inclusion\_Exclusion\_Criteria#

Treatment Assignment:

#HC\_AI\_Treatment\_Assignment#

**5. Study Assessments and Safety Monitoring**

Adverse Event (AE) Monitoring:

#HC\_AI\_AE\_Monitoring#

Laboratory and Safety Assessments:

#HC\_AI\_ Laboratory\_And\_Safety\_Assessments#

**6. Statistical Considerations**

Analysis Populations:

#HC\_AI\_Analysis\_Population#

**7. Appendices**

Prefilled examples of additional content, such as sample consent forms or regulatory compliance notes.